Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 275 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Masonic Cancer Center, University of Minnesota Clear all
Completed Phase 2 Interventional Results available

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

NCT00319748
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer
Interventions
852A
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 13, 2026, 7:50 PM EDT
Active, not recruiting No phase listed Observational Results available

Assessing the Time Demands of Cancer

NCT05708703
View directory record Official record
Conditions
Metastatic Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Birmingham, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens

NCT03978117
View directory record Official record
Conditions
Healthy
Interventions
Freeze Dried Watercress Preparation, Placebo Preparation
Dietary Supplement
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 13, 2026, 7:50 PM EDT
Recruiting Phase 2 Interventional

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

NCT07493538
View directory record Official record
Conditions
AML, MDS, Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Treosulfan, Fludarabine, Total Body Irradiation, Tacrolimus, Mycophenolate Mofetil, Cyclophosphamid, Stem Cell Infusion
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 13, 2026, 7:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

TBI Dose De-escalation for Fanconi Anemia

NCT00352976
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone Marrow Transplantation, Mycophenolate Mofetil, Sirolimus
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 13, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

NCT00392782
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 13, 2026, 7:50 PM EDT
Recruiting Phase 1 Interventional

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

NCT07560865
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Progressive Disease
Interventions
FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
Biological · Procedure · Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 13, 2026, 7:50 PM EDT
Completed No phase listed Observational Results available

App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer

NCT05502302
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 13, 2026, 7:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Observational Study of Exposure to Environmental Toxicants Among Firefighters

NCT05643014
View directory record Official record
Conditions
Healthy
Interventions
Sample collection
Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 13, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

NCT00784524
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic large multivalent immunogen breast cancer vaccine, aldesleukin
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 13, 2026, 7:50 PM EDT
Terminated Not applicable Interventional Results available

Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

NCT02156674
View directory record Official record
Conditions
Maroteaux-Lamy Syndrome
Interventions
Naglazyme®
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
3 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 13, 2026, 7:50 PM EDT
Completed Phase 1 Interventional

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

NCT00602693
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
umbilical cord blood transplantation, Allopurinol, fludarabine phosphate, Cyclophosphamide, Total body irradiation, Treg infusion, Sirolimus
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 13, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00818649
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome
Interventions
bortezomib, vorinostat
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 13, 2026, 7:50 PM EDT
Completed Phase 1 Interventional

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

NCT00095160
View directory record Official record
Conditions
Neoplasms
Interventions
852A
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 13, 2026, 7:50 PM EDT
Completed Phase 1 Interventional Results available

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

NCT04630769
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer
Interventions
IP FT516, Enoblituzumab, IL-2
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 13, 2026, 7:50 PM EDT
Withdrawn Phase 3 Interventional

Bone Marrow Transplantation in Treating Patients With Leukemia

NCT00006451
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 13, 2026, 7:50 PM EDT
Completed No phase listed Observational Results available

A Multi-Center Trial of the ProLung Test™

NCT01566682
View directory record Official record
Conditions
Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
Interventions
Not listed
Lead sponsor
Fresh Medical Laboratories
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 13, 2026, 7:50 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplantation for Hurler

NCT00176917
View directory record Official record
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Mannosidosis, Mucolipidosis Type II (I-cell Disease)
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, ATG
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 13, 2026, 7:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study

NCT01705288
View directory record Official record
Conditions
Cervical Cancer, Uterine Endometrial Cancer, Ovarian Cancer
Interventions
Laparotomy, intravenous narcotics, standard anesthesia, regional anesthesia, Non-steroidal anti-inflammatory drugs
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
19 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 13, 2026, 7:50 PM EDT
Terminated Not applicable Interventional Results available

Stem Cell Transplant for Hematological Malignancy

NCT00176930
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma
Interventions
Stem Cell Transplant, Cyclophosphamide, Total Body Irradiation, Busulfan, Equine ATG (ATGAM), CD4+/CD25+ cells
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 13, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

NCT00303719
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine, mycophenolate mofetil, stem cell transplantation, total body irradiation, filgrastim
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 13, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

Reduced Intensity AlloTransplant For Osteopetrosis

NCT00638820
View directory record Official record
Conditions
Osteopetrosis
Interventions
Stem Cell or Umbilical Cord Blood Transplantation, Campath, Busulfan, Clofarabine, Total Lymphoid Irradiation
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 13, 2026, 7:50 PM EDT
Terminated Phase 2 Interventional Results available

T-Cell Depleted Double UCB for Refractory AML

NCT01464359
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia
Interventions
Allopurinol, Fludarabine, Total body irradiation, Cyclophosphamide, Levetiracetam, Busulfan, Umbilical Cord Blood Transplantation, Interleukin-2
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 13, 2026, 7:50 PM EDT
Recruiting Phase 2 Interventional

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation, G-CSF, Cyclophosphamide, Total Body Irradiation
Drug · Procedure · Biological + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 13, 2026, 7:50 PM EDT